Spots Global Cancer Trial Database for Use of Topotecan in Patients With Refractory Acute Leukemia
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Use of Topotecan in Patients With Refractory Acute Leukemia
Official Title: Study of Topoisomerase Inhibition in the Treatment of Acute Leukemia
Study ID: NCT00100477
Study Description
Brief Summary: The purpose of this study is to identify the highest tolerated doses in drugs used to treat aggressive leukemia, lymphoma or multiple myeloma not responding to standard chemotherapy treatment. The drugs being used in this study include drugs frequently used in treating such diseases (mitoxantrone and etoposide) as well as a newer drug that has also been shown to be effective (topotecan).
Detailed Description: The purpose of this study is to identify the highest tolerated doses in drugs used to treat aggressive leukemia, lymphoma or multiple myeloma not responding to standard chemotherapy treatment. The drugs being used in this study include drugs frequently used in treating such diseases (mitoxantrone and etoposide) as well as a newer drug that has also been shown to be effective (topotecan).
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT
Sex: ALL
Healthy Volunteers: No
Locations
North Florida/South Georgia Veterans Health System, Gainesville, Florida, United States
Contact Details
Name: Mark Mainwaring
Affiliation: North Florida/South Georgia Veterans Health System
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
